Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02918994 · ClinicalTrials.gov registry record · NA

LearningRx Cognitive Training for Brain Injury

A NA study of Acquired Brain Injury and Traumatic Brain Injury (TBI), sponsored by Gibson Institute of Cognitive Research.

Active
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT02918994 is a NA study of Acquired Brain Injury and Traumatic Brain Injury (TBI) that is active but no longer recruiting, run by Gibson Institute of Cognitive Research. The registered enrollment target is 30 participants, below the 76-participant average among 10 other Acquired Brain Injury trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02918994, a NA study of Acquired Brain Injury and Traumatic Brain Injury (TBI), is active but no longer recruiting, sponsored by Gibson Institute of Cognitive Research.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this investigation is to conduct a series of case studies on the impact of LearningRx cognitive training on cognitive skills, daily functioning, and workplace self-efficacy for participants with Traumatic Brain Injury (TBI) /Acquired Brain Injury (ABI).

Interventions

  • BEHAVIORAL LearningRx cognitive training

Study Locations (1)

Colorado

  • Gibson Institute of Cognitive Research - Colorado Springs

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2016-09
Est. Completion 2027-12
Phase NA

What the Registry Record Tells You About NCT02918994

The ClinicalTrials.gov registry entry for NCT02918994 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 76-participant average among 10 other Acquired Brain Injury trials with a reported enrollment target (61% lower). The listed sponsor is Gibson Institute of Cognitive Research, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acquired Brain Injury appearing as the primary indexed condition, and to 1 intervention - of which LearningRx cognitive training is the first listed.

NCT02918994 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT02918994 about?

NCT02918994 is a clinical study titled "LearningRx Cognitive Training for Brain Injury". The purpose of this investigation is to conduct a series of case studies on the impact of LearningRx cognitive training on cognitive skills, daily functioning, and workplace self-efficacy for participants with Traumatic Brain Injury (TBI) /Acquired Brain Injury (ABI).

What is the current status of trial NCT02918994?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2016-09. Estimated completion is 2027-12.

What conditions does trial NCT02918994 study?

This clinical trial studies the following conditions: Acquired Brain Injury, Traumatic Brain Injury (TBI), Post COVID-19 Cognitive Impairment.

What interventions are being tested in trial NCT02918994?

The interventions under investigation include: LearningRx cognitive training (BEHAVIORAL).

Who is sponsoring clinical trial NCT02918994?

This trial is sponsored by Gibson Institute of Cognitive Research, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02918994 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acquired Brain Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.